A Randomized, Blinded Study of Two Doses of Novastan® (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-01

AUTHORS

Ik-Kyung Jang, Robert P. Giugliano, Thomas J. Massey, Richard P. Schwarz

ABSTRACT

Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. and incomplete myocardial perfusion. Furthermore, cyclic flow variations and reocclu.sions remain a significant cause of late morbidity and mortality. In thrombolysis with tissue plasminogen activator (t-PA), heparin seems to play an important role. However, it has several features that suggest that it may not be the optimal adjunct to thrombolytics, including weak and indirect action on thrombin, little access to clot-bound thrombin, inhibition by acute-phase plasma proteins, and its direct stimulation of platelet aggregation. Argatroban (NOVASTAN(R)), a small-molecule, synthetic, direct thrombin inhibitor, has several potential advantages over heparin, and prior studies suggest superior thrombin inhibition with favorable pharmacokinetic and pharmacodynamic properties warranting further investigation The Myocardial Infarction using NOVASTAN (R) and t-PA (MINT) study is a phase II, single-blind, angiographic trial directly comparing heparin versus two doses of argatroban in 120 patients with ST-elevation MI who present within 6 hours of symptom onset. The primary objective of the MINT trial is to assess the TIMI grade 3 flow and TIMI Frame Count at 90 minutes after the initiation of t-PA. This trial will also evaluate the safety of the combination of t-PA, argatroban, and aspirin. The incidence of clinical or silent ischemia, will be monitored. All patients will be followed up to 30 days for the composite endpoint of death, nonfatal recurrent myocardial infarction, coronary artery bypass surgery, PTCA, recurrent ischemia, and shock/new-onset heart failure. More... »

PAGES

49-52

References to SciGraph publications

  • 1995-11. The thrombin paradox in NATURE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1023/a:1008872031770

    DOI

    http://dx.doi.org/10.1023/a:1008872031770

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1050310098

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/10608050


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jang", 
            "givenName": "Ik-Kyung", 
            "id": "sg:person.0766106100.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766106100.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Giugliano", 
            "givenName": "Robert P.", 
            "id": "sg:person.0702207604.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Coromed, Inc., Albany, New York"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Massey", 
            "givenName": "Thomas J.", 
            "id": "sg:person.01111411542.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111411542.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pfizer (United States)", 
              "id": "https://www.grid.ac/institutes/grid.410513.2", 
              "name": [
                "Texas Biotechnology Corporation, Houston, Texas, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schwarz", 
            "givenName": "Richard P.", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1016/0735-1097(90)90364-u", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001926485"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.82.3.781", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002167204"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/378337a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011491741", 
              "https://doi.org/10.1038/378337a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.81.1.219", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013183576"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199311253292211", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016035046"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0735-1097(92)90265-o", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018568026"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199311253292204", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019874241"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0735-1097(94)90581-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020001364"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0002-9149(90)90525-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024723146"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.res.67.6.1552", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026582342"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.90.4.1624", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027684067"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00019501-199205000-00009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030039419"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00019501-199205000-00009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030039419"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0735-1097(89)90399-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035440842"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199011223232101", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039290762"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0735-1097(94)90163-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041087853"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.90.4.1631", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045301390"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(94)91161-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049147186"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(94)91161-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049147186"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.79.2.441", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051595207"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199309023291001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053195270"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/bi00296a014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055169132"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.91.8.2132", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1063336209"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/01.cir.93.5.879", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1063337016"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1055/s-0038-1648875", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082537423"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1998-01", 
        "datePublishedReg": "1998-01-01", 
        "description": "Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. and incomplete myocardial perfusion. Furthermore, cyclic flow variations and reocclu.sions remain a significant cause of late morbidity and mortality. In thrombolysis with tissue plasminogen activator (t-PA), heparin seems to play an important role. However, it has several features that suggest that it may not be the optimal adjunct to thrombolytics, including weak and indirect action on thrombin, little access to clot-bound thrombin, inhibition by acute-phase plasma proteins, and its direct stimulation of platelet aggregation. Argatroban (NOVASTAN(R)), a small-molecule, synthetic, direct thrombin inhibitor, has several potential advantages over heparin, and prior studies suggest superior thrombin inhibition with favorable pharmacokinetic and pharmacodynamic properties warranting further investigation The Myocardial Infarction using NOVASTAN (R) and t-PA (MINT) study is a phase II, single-blind, angiographic trial directly comparing heparin versus two doses of argatroban in 120 patients with ST-elevation MI who present within 6 hours of symptom onset. The primary objective of the MINT trial is to assess the TIMI grade 3 flow and TIMI Frame Count at 90 minutes after the initiation of t-PA. This trial will also evaluate the safety of the combination of t-PA, argatroban, and aspirin. The incidence of clinical or silent ischemia, will be monitored. All patients will be followed up to 30 days for the composite endpoint of death, nonfatal recurrent myocardial infarction, coronary artery bypass surgery, PTCA, recurrent ischemia, and shock/new-onset heart failure.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1023/a:1008872031770", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1113719", 
            "issn": [
              "0929-5305", 
              "1573-742X"
            ], 
            "name": "Journal of Thrombosis and Thrombolysis", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "5"
          }
        ], 
        "name": "A Randomized, Blinded Study of Two Doses of Novastan\u00ae (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan\u00ae and T-PA (MINT) Study", 
        "pagination": "49-52", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "efa99b5d88b0f2e7d5f234ac41849e992fa1f241f0238640b2da1e2e3e9a7a75"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "10608050"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "9502018"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1023/a:1008872031770"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1050310098"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1023/a:1008872031770", 
          "https://app.dimensions.ai/details/publication/pub.1050310098"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T21:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000501.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1023/A:1008872031770"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1008872031770'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1008872031770'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1008872031770'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1008872031770'


     

    This table displays all metadata directly associated to this object as RDF triples.

    165 TRIPLES      21 PREDICATES      52 URIs      21 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1023/a:1008872031770 schema:about anzsrc-for:11
    2 anzsrc-for:1102
    3 schema:author N305fcd355bfc403f91d1a2b1f7925c2d
    4 schema:citation sg:pub.10.1038/378337a0
    5 https://doi.org/10.1016/0002-9149(90)90525-6
    6 https://doi.org/10.1016/0735-1097(89)90399-9
    7 https://doi.org/10.1016/0735-1097(90)90364-u
    8 https://doi.org/10.1016/0735-1097(92)90265-o
    9 https://doi.org/10.1016/0735-1097(94)90163-5
    10 https://doi.org/10.1016/0735-1097(94)90581-9
    11 https://doi.org/10.1016/s0140-6736(94)91161-4
    12 https://doi.org/10.1021/bi00296a014
    13 https://doi.org/10.1055/s-0038-1648875
    14 https://doi.org/10.1056/nejm199011223232101
    15 https://doi.org/10.1056/nejm199309023291001
    16 https://doi.org/10.1056/nejm199311253292204
    17 https://doi.org/10.1056/nejm199311253292211
    18 https://doi.org/10.1097/00019501-199205000-00009
    19 https://doi.org/10.1161/01.cir.79.2.441
    20 https://doi.org/10.1161/01.cir.81.1.219
    21 https://doi.org/10.1161/01.cir.82.3.781
    22 https://doi.org/10.1161/01.cir.90.4.1624
    23 https://doi.org/10.1161/01.cir.90.4.1631
    24 https://doi.org/10.1161/01.cir.91.8.2132
    25 https://doi.org/10.1161/01.cir.93.5.879
    26 https://doi.org/10.1161/01.res.67.6.1552
    27 schema:datePublished 1998-01
    28 schema:datePublishedReg 1998-01-01
    29 schema:description Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. and incomplete myocardial perfusion. Furthermore, cyclic flow variations and reocclu.sions remain a significant cause of late morbidity and mortality. In thrombolysis with tissue plasminogen activator (t-PA), heparin seems to play an important role. However, it has several features that suggest that it may not be the optimal adjunct to thrombolytics, including weak and indirect action on thrombin, little access to clot-bound thrombin, inhibition by acute-phase plasma proteins, and its direct stimulation of platelet aggregation. Argatroban (NOVASTAN(R)), a small-molecule, synthetic, direct thrombin inhibitor, has several potential advantages over heparin, and prior studies suggest superior thrombin inhibition with favorable pharmacokinetic and pharmacodynamic properties warranting further investigation The Myocardial Infarction using NOVASTAN (R) and t-PA (MINT) study is a phase II, single-blind, angiographic trial directly comparing heparin versus two doses of argatroban in 120 patients with ST-elevation MI who present within 6 hours of symptom onset. The primary objective of the MINT trial is to assess the TIMI grade 3 flow and TIMI Frame Count at 90 minutes after the initiation of t-PA. This trial will also evaluate the safety of the combination of t-PA, argatroban, and aspirin. The incidence of clinical or silent ischemia, will be monitored. All patients will be followed up to 30 days for the composite endpoint of death, nonfatal recurrent myocardial infarction, coronary artery bypass surgery, PTCA, recurrent ischemia, and shock/new-onset heart failure.
    30 schema:genre research_article
    31 schema:inLanguage en
    32 schema:isAccessibleForFree false
    33 schema:isPartOf N3626c86bb98245b2a2d12a438a5fad20
    34 N51a93c99b339440f8583dd0c054f1b23
    35 sg:journal.1113719
    36 schema:name A Randomized, Blinded Study of Two Doses of Novastan® (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan® and T-PA (MINT) Study
    37 schema:pagination 49-52
    38 schema:productId N5949a68329bd47c7a27ed20e92b79181
    39 N7eecd24384e448da987a7af5134a3707
    40 N93ee75a6c7ad49cb887519bf924acba4
    41 Nce5a95c341f14fcfb351083aaf430c2b
    42 Nf86742dd2c5c4c3e8836a3c366a0e6de
    43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050310098
    44 https://doi.org/10.1023/a:1008872031770
    45 schema:sdDatePublished 2019-04-10T21:34
    46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    47 schema:sdPublisher N444c3275642e4feb9eee8cb43ac0f110
    48 schema:url http://link.springer.com/10.1023/A:1008872031770
    49 sgo:license sg:explorer/license/
    50 sgo:sdDataset articles
    51 rdf:type schema:ScholarlyArticle
    52 N12f0e894bbef4fb1b1168abe0dd5a15d schema:name Coromed, Inc., Albany, New York
    53 rdf:type schema:Organization
    54 N1ed2f7595b5647f7a58a288aab130c32 rdf:first sg:person.0702207604.00
    55 rdf:rest N2669700c443240599681b262cdbadc63
    56 N2669700c443240599681b262cdbadc63 rdf:first sg:person.01111411542.20
    57 rdf:rest N376945eb2e7f406a8984846bd39efae8
    58 N305fcd355bfc403f91d1a2b1f7925c2d rdf:first sg:person.0766106100.00
    59 rdf:rest N1ed2f7595b5647f7a58a288aab130c32
    60 N3626c86bb98245b2a2d12a438a5fad20 schema:issueNumber 1
    61 rdf:type schema:PublicationIssue
    62 N376945eb2e7f406a8984846bd39efae8 rdf:first Ne6bde38c69fe4b45b71ad4faa9e1f82d
    63 rdf:rest rdf:nil
    64 N444c3275642e4feb9eee8cb43ac0f110 schema:name Springer Nature - SN SciGraph project
    65 rdf:type schema:Organization
    66 N51a93c99b339440f8583dd0c054f1b23 schema:volumeNumber 5
    67 rdf:type schema:PublicationVolume
    68 N5949a68329bd47c7a27ed20e92b79181 schema:name nlm_unique_id
    69 schema:value 9502018
    70 rdf:type schema:PropertyValue
    71 N7eecd24384e448da987a7af5134a3707 schema:name readcube_id
    72 schema:value efa99b5d88b0f2e7d5f234ac41849e992fa1f241f0238640b2da1e2e3e9a7a75
    73 rdf:type schema:PropertyValue
    74 N93ee75a6c7ad49cb887519bf924acba4 schema:name doi
    75 schema:value 10.1023/a:1008872031770
    76 rdf:type schema:PropertyValue
    77 Nce5a95c341f14fcfb351083aaf430c2b schema:name pubmed_id
    78 schema:value 10608050
    79 rdf:type schema:PropertyValue
    80 Ncfcb643f6d74444d94d66d23be1fb200 schema:name Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts
    81 rdf:type schema:Organization
    82 Ne12be9f563f44a43aaab060c2262965e schema:name Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts
    83 rdf:type schema:Organization
    84 Ne6bde38c69fe4b45b71ad4faa9e1f82d schema:affiliation https://www.grid.ac/institutes/grid.410513.2
    85 schema:familyName Schwarz
    86 schema:givenName Richard P.
    87 rdf:type schema:Person
    88 Nf86742dd2c5c4c3e8836a3c366a0e6de schema:name dimensions_id
    89 schema:value pub.1050310098
    90 rdf:type schema:PropertyValue
    91 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    92 schema:name Medical and Health Sciences
    93 rdf:type schema:DefinedTerm
    94 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    95 schema:name Cardiorespiratory Medicine and Haematology
    96 rdf:type schema:DefinedTerm
    97 sg:journal.1113719 schema:issn 0929-5305
    98 1573-742X
    99 schema:name Journal of Thrombosis and Thrombolysis
    100 rdf:type schema:Periodical
    101 sg:person.01111411542.20 schema:affiliation N12f0e894bbef4fb1b1168abe0dd5a15d
    102 schema:familyName Massey
    103 schema:givenName Thomas J.
    104 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111411542.20
    105 rdf:type schema:Person
    106 sg:person.0702207604.00 schema:affiliation Ncfcb643f6d74444d94d66d23be1fb200
    107 schema:familyName Giugliano
    108 schema:givenName Robert P.
    109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00
    110 rdf:type schema:Person
    111 sg:person.0766106100.00 schema:affiliation Ne12be9f563f44a43aaab060c2262965e
    112 schema:familyName Jang
    113 schema:givenName Ik-Kyung
    114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766106100.00
    115 rdf:type schema:Person
    116 sg:pub.10.1038/378337a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011491741
    117 https://doi.org/10.1038/378337a0
    118 rdf:type schema:CreativeWork
    119 https://doi.org/10.1016/0002-9149(90)90525-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024723146
    120 rdf:type schema:CreativeWork
    121 https://doi.org/10.1016/0735-1097(89)90399-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035440842
    122 rdf:type schema:CreativeWork
    123 https://doi.org/10.1016/0735-1097(90)90364-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1001926485
    124 rdf:type schema:CreativeWork
    125 https://doi.org/10.1016/0735-1097(92)90265-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1018568026
    126 rdf:type schema:CreativeWork
    127 https://doi.org/10.1016/0735-1097(94)90163-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041087853
    128 rdf:type schema:CreativeWork
    129 https://doi.org/10.1016/0735-1097(94)90581-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020001364
    130 rdf:type schema:CreativeWork
    131 https://doi.org/10.1016/s0140-6736(94)91161-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049147186
    132 rdf:type schema:CreativeWork
    133 https://doi.org/10.1021/bi00296a014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055169132
    134 rdf:type schema:CreativeWork
    135 https://doi.org/10.1055/s-0038-1648875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082537423
    136 rdf:type schema:CreativeWork
    137 https://doi.org/10.1056/nejm199011223232101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039290762
    138 rdf:type schema:CreativeWork
    139 https://doi.org/10.1056/nejm199309023291001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053195270
    140 rdf:type schema:CreativeWork
    141 https://doi.org/10.1056/nejm199311253292204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019874241
    142 rdf:type schema:CreativeWork
    143 https://doi.org/10.1056/nejm199311253292211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016035046
    144 rdf:type schema:CreativeWork
    145 https://doi.org/10.1097/00019501-199205000-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030039419
    146 rdf:type schema:CreativeWork
    147 https://doi.org/10.1161/01.cir.79.2.441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051595207
    148 rdf:type schema:CreativeWork
    149 https://doi.org/10.1161/01.cir.81.1.219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013183576
    150 rdf:type schema:CreativeWork
    151 https://doi.org/10.1161/01.cir.82.3.781 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002167204
    152 rdf:type schema:CreativeWork
    153 https://doi.org/10.1161/01.cir.90.4.1624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027684067
    154 rdf:type schema:CreativeWork
    155 https://doi.org/10.1161/01.cir.90.4.1631 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045301390
    156 rdf:type schema:CreativeWork
    157 https://doi.org/10.1161/01.cir.91.8.2132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063336209
    158 rdf:type schema:CreativeWork
    159 https://doi.org/10.1161/01.cir.93.5.879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063337016
    160 rdf:type schema:CreativeWork
    161 https://doi.org/10.1161/01.res.67.6.1552 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026582342
    162 rdf:type schema:CreativeWork
    163 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
    164 schema:name Texas Biotechnology Corporation, Houston, Texas, USA
    165 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...